Joohyong Kim, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,750 of the $7,383 with a category attached, or 77.9%. It is spread thinly across 45 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,097 and has fallen 56.3% since, to $916 in 2025. Among urology clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$1K
- Astellas Pharma US Inc$669
- AbbVie$534
- Johnson & Johnson$508
- Sumitomo Pharma America, Inc.$399
- Biofire Diagnostics, LLC$300
- plus $4K from 39 others
What the payments were for
- Consulting fees$1001%
- Speaking & faculty fees$3004%
- Travel & lodging$1,07215%
- Food & beverage$5,75078%
- Education$270%
- Gifts$1352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,383 in reported general payments places this provider in the 90th percentile of 33 urology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 35 | $495,156 |
| MyrbetriqMirabegron | 190 | $185,626 |
| OrgovyxRelugolix | 27 | $72,720 |
| TrelstarTriptorelin Pamoate | 15 | $60,866 |
| GemtesaVibegron | 62 | $60,168 |
| Tamsulosin Hcl | 948 | $18,585 |
| Mirabegron ErMirabegron | 15 | $12,357 |
| Finasteride | 337 | $6,509 |
| Silodosin | 34 | $5,144 |
| Potassium Citrate ErPotassium Citrate | 24 | $3,853 |
| Dutasteride | 45 | $3,053 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 12 | $2,920 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 158 | $2,807 |
| Testosterone | 30 | $2,587 |
| Tolterodine Tartrate ErTolterodine Tartrate | 15 | $2,426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $669 | $680,782225 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $399 | $132,88889 claims |
| Verity Pharmaceuticals Inc.Trelstar | $79 | $60,86615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 33 urology providers in Delaware.
Other urology in Dover
- Christopher VallorosiDover$7K
- Michael ZaragozaDover$6K
- Gregory SpanaDover$5K
- Raj KurpadDover$3K
- Donald SuhDover$2K
- Jason WaltherDover$87
- Christopher MitchellWilmington$19K
- Michael LobisWilmington$8K
- Thomas DesperitoWilmington$7K
- Raymond BolognaMilford$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.